Molecular eidemiology of carbapenem-resistant Enterobacter cloacae complex in a tertiary hospital in Shandong, China.
Humans
Enterobacter cloacae
/ genetics
Anti-Bacterial Agents
/ pharmacology
Carbapenems
/ pharmacology
Tertiary Care Centers
Multilocus Sequence Typing
Enterobacteriaceae Infections
/ epidemiology
beta-Lactamases
/ genetics
Bacterial Proteins
/ genetics
Carbapenem-Resistant Enterobacteriaceae
/ genetics
China
/ epidemiology
Microbial Sensitivity Tests
Carbapenemase
Enterobacter cloacae complex
NDM-1
NDM-5
ST171
ST418
Journal
BMC microbiology
ISSN: 1471-2180
Titre abrégé: BMC Microbiol
Pays: England
ID NLM: 100966981
Informations de publication
Date de publication:
05 07 2023
05 07 2023
Historique:
received:
01
11
2022
accepted:
27
06
2023
medline:
7
7
2023
pubmed:
6
7
2023
entrez:
5
7
2023
Statut:
epublish
Résumé
The increasing incidence and prevalence of carbapenem-resistant Enterobacter cloacae complex (CREC) poses great challenges to infection prevention and disease treatment. However, much remains unknown about the clinical characteristics of CREC isolates. Our objective was to characterize antimicrobial resistance and, carbapenemase production in CREC with 36 CREC isolates collected from a tertiary hospital in Shandong, China. Three types of carbapenemases (NDM, IMP and VIM) were detected in these isolates. Among them, NDM carbapenemases were most prevalent, with a 61.2% (22/36) detection rate for NDM-1, 27.8% (10/36) for NDM-5 and 2.8% (1/36) for NDM-7. IMP-4 was found in two isolates and VIM-1 in only one isolate. The MLST analysis identified 12 different sequence types (STs), of which ST171 (27.8%) was the most prevalent, followed by ST418 (25.0%). ST171 isolates had significantly higher rates of resistance than other STs to gentamicin and tobramycin (Ps < 0.05), and lower rates of resistance to aztreonam than ST418 and other STs (Ps < 0.05). Among 17 carbapenemase-encoding genes, the bla NDM-5 produced by ST171 and NDM-1 carbapenemase produced by ST418 were the leading cause of CREC in this hospital. This study enhances the understanding of CREC strains and helps improve infection control and treatment in hospitals.
Sections du résumé
BACKGROUND
The increasing incidence and prevalence of carbapenem-resistant Enterobacter cloacae complex (CREC) poses great challenges to infection prevention and disease treatment. However, much remains unknown about the clinical characteristics of CREC isolates. Our objective was to characterize antimicrobial resistance and, carbapenemase production in CREC with 36 CREC isolates collected from a tertiary hospital in Shandong, China.
RESULTS
Three types of carbapenemases (NDM, IMP and VIM) were detected in these isolates. Among them, NDM carbapenemases were most prevalent, with a 61.2% (22/36) detection rate for NDM-1, 27.8% (10/36) for NDM-5 and 2.8% (1/36) for NDM-7. IMP-4 was found in two isolates and VIM-1 in only one isolate. The MLST analysis identified 12 different sequence types (STs), of which ST171 (27.8%) was the most prevalent, followed by ST418 (25.0%). ST171 isolates had significantly higher rates of resistance than other STs to gentamicin and tobramycin (Ps < 0.05), and lower rates of resistance to aztreonam than ST418 and other STs (Ps < 0.05). Among 17 carbapenemase-encoding genes, the bla
CONCLUSION
NDM-5 produced by ST171 and NDM-1 carbapenemase produced by ST418 were the leading cause of CREC in this hospital. This study enhances the understanding of CREC strains and helps improve infection control and treatment in hospitals.
Identifiants
pubmed: 37407923
doi: 10.1186/s12866-023-02913-x
pii: 10.1186/s12866-023-02913-x
pmc: PMC10320948
doi:
Substances chimiques
Anti-Bacterial Agents
0
Carbapenems
0
beta-Lactamases
EC 3.5.2.6
Bacterial Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
177Informations de copyright
© 2023. The Author(s).
Références
Emerg Infect Dis. 2018 Jun;24(6):1010-1019
pubmed: 29774858
Emerg Infect Dis. 2011 Oct;17(10):1791-8
pubmed: 22000347
Front Microbiol. 2017 Nov 28;8:2343
pubmed: 29326660
Clin Microbiol Rev. 2007 Jul;20(3):440-58, table of contents
pubmed: 17630334
Front Microbiol. 2020 Feb 11;11:121
pubmed: 32117144
Antimicrob Agents Chemother. 2011 Nov;55(11):4943-60
pubmed: 21859938
Microb Drug Resist. 2021 May;27(5):706-709
pubmed: 33090069
PLoS One. 2015 Aug 11;10(8):e0135044
pubmed: 26263489
Antimicrob Resist Infect Control. 2020 Jan 13;9(1):15
pubmed: 31956404
Infect Drug Resist. 2021 Sep 07;14:3647-3658
pubmed: 34522107
J Infect Dis. 2017 Feb 15;215(suppl_1):S28-S36
pubmed: 28375512
J Clin Microbiol. 2016 Mar;54(3):529-34
pubmed: 26739152
BMC Microbiol. 2021 Jul 8;21(1):208
pubmed: 34238225
Antimicrob Agents Chemother. 2015 Dec;59(12):7723-34
pubmed: 26438492
PLoS One. 2016 Jan 25;11(1):e0147639
pubmed: 26808495
Future Microbiol. 2012 Jul;7(7):887-902
pubmed: 22827309
Diagn Microbiol Infect Dis. 2015 Apr;81(4):264-8
pubmed: 25680336
BMC Infect Dis. 2021 Jun 26;21(1):611
pubmed: 34174823
J Glob Antimicrob Resist. 2013 Mar;1(1):7-16
pubmed: 27873609
BMC Infect Dis. 2020 Apr 16;20(1):282
pubmed: 32299378
mBio. 2018 May 29;9(3):
pubmed: 29844109
Antimicrob Agents Chemother. 2008 Aug;52(8):2984-7
pubmed: 18490506
J Antimicrob Chemother. 2016 Aug;71(8):2351-3
pubmed: 27118776
Front Cell Infect Microbiol. 2020 Jul 03;10:314
pubmed: 32719751
Diagn Microbiol Infect Dis. 2011 May;70(1):119-23
pubmed: 21398074
Antimicrob Agents Chemother. 2015 Jul;59(7):4059-66
pubmed: 25918153
Front Microbiol. 2019 Jan 31;10:44
pubmed: 30766518
PLoS One. 2017 Dec 15;12(12):e0189713
pubmed: 29244831
Clin Microbiol Rev. 2019 Jul 17;32(4):
pubmed: 31315895
Ann N Y Acad Sci. 2013 Jan;1277:91-104
pubmed: 23163348
Clin Microbiol Rev. 2012 Oct;25(4):682-707
pubmed: 23034326
Int J Antimicrob Agents. 2015 Oct;46(4):469-74
pubmed: 26307466
Virulence. 2017 May 19;8(4):460-469
pubmed: 27593176
JAC Antimicrob Resist. 2021 Jul 16;3(3):dlab092
pubmed: 34286272
Front Microbiol. 2017 Jan 31;8:94
pubmed: 28197140
Antimicrob Agents Chemother. 2009 Dec;53(12):5046-54
pubmed: 19770275
Front Microbiol. 2018 Jul 17;9:1597
pubmed: 30065717
Antibiotics (Basel). 2021 Jun 10;10(6):
pubmed: 34200675
Antimicrob Resist Infect Control. 2013 Dec 18;2(1):35
pubmed: 24345195
J Antimicrob Chemother. 2015 Jan;70(1):48-56
pubmed: 25216820
J Antimicrob Chemother. 2017 Aug 1;72(8):2249-2258
pubmed: 28520983
Emerg Infect Dis. 2014 Sep;20(9):1583-5
pubmed: 25153967